Eli Lilly & Co. (LLY)

117.98
1.40 1.20
NYSE : Health Technology
Prev Close 116.58
Open 116.12
Day Low/High 116.12 / 118.39
52 Wk Low/High 81.61 / 132.13
Volume 3.93M
Avg Volume 15.91M
Exchange NYSE
Shares Outstanding 970.83M
Market Cap 112.63B
EPS 3.10
P/E Ratio 44.70
Div & Yield 2.58 (2.01%)

Latest News

Lilly To Participate In UBS Global Healthcare Conference

Lilly To Participate In UBS Global Healthcare Conference

INDIANAPOLIS, May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019.

Data Presentations At ASCO 2019 Highlight Lilly's Targeted Approach To Developing Treatments For Patients Living With Cancer

Data Presentations At ASCO 2019 Highlight Lilly's Targeted Approach To Developing Treatments For Patients Living With Cancer

Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189

Lilly To Participate In Bank Of America Merrill Lynch Health Care Conference

Lilly To Participate In Bank Of America Merrill Lynch Health Care Conference

INDIANAPOLIS, May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019.

Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy In Patients With Hepatocellular Carcinoma

Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy In Patients With Hepatocellular Carcinoma

This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, GMRE, ISSC, JCI, MKL, NFBK, SUN Downgrades: AAOI, AAON, ACIW, CRCM, ENV, LLY, MOS, OFIX, PAGP, PYX, RGNX, SAIL, TTD Initiations: CLNC, VBLT Read on to get TheStreet Quant Ratings' detailed report:

AAN 2019: Two New Analyses Of Lasmiditan Phase 3 Studies Measured Onset Of Effect And The Effect Of Lasmiditan In Patients With Prior Triptan Experience

AAN 2019: Two New Analyses Of Lasmiditan Phase 3 Studies Measured Onset Of Effect And The Effect Of Lasmiditan In Patients With Prior Triptan Experience

- The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks[1,2,3]

Lilly Declares Second-Quarter 2019 Dividend

Lilly Declares Second-Quarter 2019 Dividend

INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.

AAN 2019: Pooled Analyses Of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction In Monthly Migraine Headache Days In Low- And High-Frequency Episodic Migraine Subgroups

AAN 2019: Pooled Analyses Of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction In Monthly Migraine Headache Days In Low- And High-Frequency Episodic Migraine Subgroups

INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies.

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Lilly To Present New Data At AAN 2019 On Emgality® (galcanezumab-gnlm) And Lasmiditan Reinforcing Breadth Of Headache Disorders Portfolio

Lilly To Present New Data At AAN 2019 On Emgality® (galcanezumab-gnlm) And Lasmiditan Reinforcing Breadth Of Headache Disorders Portfolio

- 19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation

Eli Lilly Reports Better-Than-Expected Earnings but Shares Decline

Eli Lilly Reports Better-Than-Expected Earnings but Shares Decline

The company expects fiscal-year adjusted earnings of $5.60 to $5.70 a share.

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance To Reflect Disposition Of Elanco Animal Health

Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance To Reflect Disposition Of Elanco Animal Health

- Revenue in the first quarter of 2019 grew 3 percent, driven by 7 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39 percent of revenue and delivered strong volume growth.

U.S. Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

U.S. Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit

INDIANAPOLIS, April 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

Lilly To Establish An Access Program For Patients As It Prepares To Withdraw Lartruvo From The Global Market

Lilly To Establish An Access Program For Patients As It Prepares To Withdraw Lartruvo From The Global Market

Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market

Lilly Announces Sale Of Legacy Antibiotics Brands And Manufacturing Facility In China

Lilly Announces Sale Of Legacy Antibiotics Brands And Manufacturing Facility In China

INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ®, as well as a manufacturing...

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.

Lilly Announces Positive Top-Line Results For COAST-X, A 52-Week Placebo-Controlled Study Of Taltz® (ixekizumab) In Patients With Non-Radiographic Axial Spondyloarthritis

Lilly Announces Positive Top-Line Results For COAST-X, A 52-Week Placebo-Controlled Study Of Taltz® (ixekizumab) In Patients With Non-Radiographic Axial Spondyloarthritis

INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the...

Lilly And Avidity Biosciences Announce Licensing And Research Collaboration

Lilly And Avidity Biosciences Announce Licensing And Research Collaboration

-Collaboration will pursue therapeutic targets focused on immunology and other indications

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

If you want a good read on the economy, look at the details of CSX's latest earnings report.

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.

Lilly Confirms Date And Conference Call For First-Quarter 2019 Financial Results Announcement

Lilly Confirms Date And Conference Call For First-Quarter 2019 Financial Results Announcement

INDIANAPOLIS, April 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019.

Arteaus Therapeutics Sells Emgality Royalty To Royalty Pharma For $260 Million

Arteaus Therapeutics Sells Emgality Royalty To Royalty Pharma For $260 Million

NEW YORK, April 1, 2019 /PRNewswire/ -- Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli...

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Lilly And ImmuNext Announce Licensing And Research Collaboration

Lilly And ImmuNext Announce Licensing And Research Collaboration

INDIANAPOLIS and LEBANON, N.H.

NCCN Announces Six Quality Improvement Projects In Gastric Cancer Care Approved For Collaboration With Lilly Oncology

NCCN Announces Six Quality Improvement Projects In Gastric Cancer Care Approved For Collaboration With Lilly Oncology

PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ®) Oncology Research Program ( ORP) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the...

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

TheStreet Quant Rating: C+ (Hold)